Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers
Status:
Not yet recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg
versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline
pathological mismatch repair gene defect, Lynch Syndrome. Project 3 in the Cancer Prevention
Programme (CaPP3).
Phase:
Phase 3
Details
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Collaborators:
Rabin Medical Center Rambam Health Care Campus Sheba Academic Medical Center Hospital Soroka Medical Center Soroka University Medical Center